Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL2107 vs Keytruda adjuvant PK similarity study in resected NSCLC
CTR20254303Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL2107 in non-small cell lung cancer (NSCLC), sponsored by Qilu Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
QL2107
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20254303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254303.